Kilitch Drugs says it will divest its Ethiopian subsidiary stake for $14 million. The company frames the move as a portfolio optimisation step rather than an operational reversal, with proceeds intended for financial and business priorities.
Across sources, the core transaction terms match: a $14 million divestment tied to Kilitch Drugs’ Ethiopian exposure. The outlets differ slightly in wording about what is being sold—one describes divesting the Ethiopian arm, while the other specifies divesting the entire stake. Both also describe how the proceeds are expected to be used, including strengthening financial flexibility and supporting investment and expansion plans for Kilitch Drugs’ pharmaceutical manufacturing in India, as well as debt-related needs and growth in its core business.